secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2026-05-11T20:05:34+00:00
Accession:  0001193125-26-216743
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Q1 net loss $33.7M; Phase 3 CoMpass enrollment mid-2026; new CEO appointed
-------------------------------------------------------------------------------

- Net loss of $33.7M in Q1 2026; R&D expenses $28.0M (up from $23.3M) reflecting Phase 3 costs.
- Phase 3 CoMpass trial in early choroidal melanoma enrollment expected to complete mid-2026; topline data in 2H 2027.
- Natalie Holles appointed CEO and President effective April 30, 2026, succeeding founder Elisabet de los Pinos.
- Completed $299M equity offering (net ~$280.8M); used $39M to repurchase shares from Matrix Capital; cash into 2H 2028.
- Pipeline: Phase 2 choroidal metastases data in 2026; Phase 1 ocular cancer PoC data in 2026; bladder cancer data mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/0001193125-26-216743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526216743/aura-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer